TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB - PubMed (original) (raw)
. 2003 Jun 19;22(25):3842-52.
doi: 10.1038/sj.onc.1206520.
Affiliations
- PMID: 12813457
- DOI: 10.1038/sj.onc.1206520
TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB
Harald Ehrhardt et al. Oncogene. 2003.
Abstract
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a potent inducer of apoptosis in cancer cells. Examining primary cells of children with untreated acute leukemia, TRAIL induced apoptosis in 50% of cells, but to our surprise attenuated spontaneous apoptosis in the remaining samples or, most importantly, even mediated proliferation. We therefore examined tumor cell lines of leukemic and nonleukemic origin with apoptosis resistance towards TRAIL because of absent Caspase-8 or dysfunctional FADD. In all cell lines tested, TRAIL treatment increased cell numbers in average to 163% within 4 days and accelerated doubling time from 24 to 19 h. TRAIL-mediated proliferation was completely abrogated by blockade of NF-kappaB activation using proteasome inhibitors or in RIP-negative, IKKgamma-negative cells or in cells overexpressing dominant-negative IkappaBalpha. Our data describe the biological significance of TRAIL-mediated activation of NF-kappaB in cancer cells resistant to TRAIL-mediated apoptosis: TRAIL leads to an increase in tumor cell count by a prosurvival and possibly mitogenic function. Given the promising therapeutic potential of TRAIL as a novel anticancer drug, TRAIL-mediated survival or proliferation of target cells may restrict its use to apoptosis-sensitive tumors.
Similar articles
- Cooperative cytotoxicity of proteasome inhibitors and tumor necrosis factor-related apoptosis-inducing ligand in chemoresistant Bcl-2-overexpressing cells.
Nencioni A, Wille L, Dal Bello G, Boy D, Cirmena G, Wesselborg S, Belka C, Brossart P, Patrone F, Ballestrero A. Nencioni A, et al. Clin Cancer Res. 2005 Jun 1;11(11):4259-65. doi: 10.1158/1078-0432.CCR-04-2496. Clin Cancer Res. 2005. PMID: 15930365 - Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II.
Ravi R, Bedi A. Ravi R, et al. Cancer Res. 2002 Aug 1;62(15):4180-5. Cancer Res. 2002. PMID: 12154014 - TRAIL-mediated apoptosis requires NF-kappaB inhibition and the mitochondrial permeability transition in human hepatoma cells.
Kim YS, Schwabe RF, Qian T, Lemasters JJ, Brenner DA. Kim YS, et al. Hepatology. 2002 Dec;36(6):1498-508. doi: 10.1053/jhep.2002.36942. Hepatology. 2002. PMID: 12447876 - Regulation of sensitivity to TRAIL by the PTEN tumor suppressor.
Whang YE, Yuan XJ, Liu Y, Majumder S, Lewis TD. Whang YE, et al. Vitam Horm. 2004;67:409-26. doi: 10.1016/S0083-6729(04)67021-X. Vitam Horm. 2004. PMID: 15110188 Review. - Regulation of TRAIL-induced apoptosis by ectopic expression of antiapoptotic factors.
Aggarwal BB, Bhardwaj U, Takada Y. Aggarwal BB, et al. Vitam Horm. 2004;67:453-83. doi: 10.1016/S0083-6729(04)67023-3. Vitam Horm. 2004. PMID: 15110190 Review.
Cited by
- Molecular signatures in prion disease: altered death receptor pathways in a mouse model.
Giri RK. Giri RK. J Transl Med. 2024 May 27;22(1):503. doi: 10.1186/s12967-024-05121-x. J Transl Med. 2024. PMID: 38802941 Free PMC article. - TRAIL predisposes non-small cell lung cancer to ferroptosis by regulating ASK-1/JNK1 pathway.
Liu X, Deng H, Huang M, Zhou W, Yang Y. Liu X, et al. Discov Oncol. 2024 Feb 21;15(1):45. doi: 10.1007/s12672-024-00890-9. Discov Oncol. 2024. PMID: 38383815 Free PMC article. - Genetically Engineered-Cell-Membrane Nanovesicles for Cancer Immunotherapy.
Cheng Q, Kang Y, Yao B, Dong J, Zhu Y, He Y, Ji X. Cheng Q, et al. Adv Sci (Weinh). 2023 Sep;10(26):e2302131. doi: 10.1002/advs.202302131. Epub 2023 Jul 6. Adv Sci (Weinh). 2023. PMID: 37409429 Free PMC article. Review. - The Role of TRAIL in Apoptosis and Immunosurveillance in Cancer.
Pimentel JM, Zhou JY, Wu GS. Pimentel JM, et al. Cancers (Basel). 2023 May 13;15(10):2752. doi: 10.3390/cancers15102752. Cancers (Basel). 2023. PMID: 37345089 Free PMC article. Review. - TRAIL receptors promote constitutive and inducible IL-8 secretion in non-small cell lung carcinoma.
Favaro F, Luciano-Mateo F, Moreno-Caceres J, Hernández-Madrigal M, Both D, Montironi C, Püschel F, Nadal E, Eldering E, Muñoz-Pinedo C. Favaro F, et al. Cell Death Dis. 2022 Dec 15;13(12):1046. doi: 10.1038/s41419-022-05495-0. Cell Death Dis. 2022. PMID: 36522309 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous